THE PREVALENCE AND CLINICAL MANIFESTATIONS OF TUBERCULOSIS AND THE EFFICIENCY OF ITS TREATMENT IN PATIENTS WITH DIABETES MELLITUS

Download full text PDF
Issue: 
2
Year: 
2017

Professor O. Komissarova (1, 2), MD; Professor R. Abdullaev (1), MD; O. Konyaeva (1); O. Berezhnaya (1, 2); A. Mikhailovsky (3) 1-Central Research Institute of Tuberculosis, Moscow 2-N.I. Pirogov Russian National Research Medical University, Moscow 3-Orenburg Regional Clinical Tuberculosis Dispensary

The paper gives data on the prevalence of tuberculosis concurrent with diabetes mellitus in different regions of the world and on the clinical, radiological, and laboratory manifestations of this disease.

Keywords: 
phthisiology
tuberculosis
diabetes mellitus
prevalence
clinical manifestations
treatment
efficiency



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. WHO/HTM/TB/2015.22 Global Tuberculosis report 2015. [Electronic resource] //URL: http://www.who.int/tb/publications/global_report/en.
  2. Nechaeva O.B. Predvaritel'nye rezul'taty epidemiologicheskih pokazatelej po tuberkulezu za 2015 god. [Elektronnyj resurs]: http://www.mednet.ru/ru/czentr-monitoringa-tuberkuleza.html
  3. IDF Diabetes Atlas. Seventh Edition revision 2015 [Electronic resource] URL: http://www.idf.org/diabetesatlas
  4. Dedov I.I., Shestakova M.V. Algoritm spetsializirovannoj meditsinskoj pomoschi bol'nym saharnym diabetom // Saharnyj diabet. – 2015; 1: 1–112.
  5. Gosregistr SD Dannye 2000–2015. [Elektronnyj resurs]: http://diaregistry.ru
  6. Corbett E., Watt C., Walker N. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic // Arch. Intern. Med. – 2003; 169: 1009–21.
  7. Deklaratsija Bali o nadvigajuschiesja ko-epidemii: tuberkulez i saharnyj diabet. [Elektronnyj resurs]: http://www.worlddiabetesfoundation.org/news/bali-declaration-calls-action-against-tb-diabetes-co-epidemic
  8. Komissarova O.G. Tuberkulez legkih u bol'nyh saharnym diabetom // Tuberkulez i bolezni legkih. – 2012; 11: 3–7.
  9. Leung C., Lam T., Chan W. et al. Diabetic Control and Risk of Tuberculosis: A Cohort Study // Am. J. Epidemiol. – 2008; 167: 1486–94.
  10. Dooley K., Chaisson R. Tuberculosis and diabetes mellitus: convergence of two epidemics // Lancet Infect. Dis. – 2009; 9: 737–46.
  11. Smurova T.F., Kovaleva S.I. Tuberkulez i saharnyj diabet / M.: Medkniga, 2007; 317 s.
  12. Niazi A., Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control // J. Diabet. Metabol. Disord. – 2012; 11: e28.
  13. van Crevel R., Beiger M. Ottenhoff T. et al. Possible mechanisms underlying increased susceptibility of diabetes patients to TB // Int. J. Tuberc. Lung Dis. – 2014; 18 (Suppl. 1): S5.
  14. Martens G., Arikan M., Lee J. et al. Tuberculosis Susceptibility of Diabetic Mice // Am. J. Repir. Cell Molecul. Biol. – 2007; 37: 518–24.
  15. Restrepo B., Fisher-Hoch S., Pino P. Tuberculosis in Poorly Controlled Type 2 Diabetes: Altered Cytokine Expression in Peripheral White Blood Cells // Clin. Infect. Dis. – 2008; 47: 634–41.
  16. Yamashiro S., Kawakami K., Uezu K. et al. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis // Clin. Exp. Immunol. – 2005; 139: 57–64.
  17. Al-Attiyah R., Mustafa A. Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guérin (BCG)-vaccinated healthy subjects // Clin. Exp. Immunol. – 2009; 158: 64–73.
  18. Kostenko A.D. Hirurgicheskoe i konservativnoe lechenie bol'nyh tuberkulezom v sochetanii s saharnym diabetom. Avtoref. dis. … kand. med nauk. M., 2003; 16 s.
  19. Alisjahbana B., Sahiratmadja E., Nelwan E. et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis // Clin. Infect. Dis. – 2007; 45: 428–35.
  20. Tatar D., Senol G., Alptekin S. et al. Tuberculosis in diabetics: features in an endemic area // Jpn. J. Infect. Dis. – 2009; 62: 423–7.
  21. Wu Z., Guo J., Huang Y. et al. Impact of diabetes mellitus on clinical presentation and treatment outcome of pulmonary tuberculosis in an urban area in China // Int. J. Tuberc. Lung Dis. – 2014; 18 (Suppl. 1): S240.
  22. Costa J., Gomes M., Duarte R. Diabetes mellitus and pulmonary tuberculosis – Portuguese retrospective cohort // Eur. Resp. Dis. – 2015; 46 (Suppl. 59): 2723.
  23. Abdulrazaq M., Alfarttoosi A. Prevalence of diabetes mellitus in new tuberculosis cases in Baghdad // Eur. Resp. Dis. – 2015; 46 (Suppl. 59): 2726.
  24. Balakrishnan S., Vijayan S., Nair S. et al. High diabetes prevalence among tuberculosis cases in Kerala, India // PLoS Med. – 2012; 7: e46502.
  25. Perez-Guzman C., Torres-Cruz A., Villarreal-Velarde H. et al. Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes // Am. J. Respir. Crit. Care Med. – 2000; 162: 1738–40.
  26. Komissarova O.G., Konjaeva O.O., Berezhnaja O.O. i dr. Sravnitel'nyj analiz klinicheskih projavlenij tuberkuleza legkih s lekarstvennoj ustojchivost'ju vozbuditelja u bol'nyh s soputstvujuschim saharnym diabetom i bez nego // Tuberkulez i bolezni legkih. – 2015; 6: 80.
  27. Skowronski M., Zozulinska-Ziołkiewicz D., Barinow-Wojewodzki A. Tuberculosis and diabetes mellitus – an underappreciated association // Arch. Med. Sci. – 2014; 10: 1019–27.
  28. Dooley K. Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis // Am. J. Trop. Med. Hyg. – 2009; 80: 634–9.
  29. Dye C., Glaziou P., Floyd K. et al. Prospects for tuberculosis elimination // Ann. Rev. Public Health. – 2013; 34: 271–86.
  30. Kovaleva S.I. Saharnyj diabet i tuberkulez (dispansernoe issledovanie). Avtoref. dis. … d-ra med nauk. M., 1979; 36 s.
  31. Singla R., Khan N., Al-Sharif N. et al. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients // Int. J. Tuberc. Lung Dis. – 2006; 10: 74–9.
  32. Perez-Guzman C., Torres-Cruz A., Villarreal-Velarde H. et al. Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: a comparative study // Int. J. Tuberc. Lung Dis. – 2001; 5: 455–61.
  33. Komissarova O.G. Konjaeva O.O., Berezhnaja O.O. i dr. Osobennosti techenija tuberkuleza legkih u bol'nyh s soputstvujuschim saharnym diabetom // Ftiziat. i pul'monol. – 2016; 1: 42–4.
  34. Punga V., Yakimova M., Rusakova L. Impact of diabetes mellitus on epidemiological rates of pulmonary tuberculosis // Int. J. Tuberc. Lung Dis. – 2014; 18 (Suppl. 1): S308.
  35. Chiang C., Bai K., Lin H. et al. The Influence of Diabetes, Glycemic Control, and Diabetes-Related Comorbidities on Pulmonary Tuberculosis // PLoS One. – 2015; 10: e0121698.
  36. Zhang Q., Xiao H., Sugawara I. Tuberculosis complicated by Diabetes Mellitus of Shanghai Pulmonary Hospital, China // Jpn. Infect. Dis. – 2009; 62: 390–1.
  37. Baker M., Harries A., Jeon C. et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review // BMC Medicine. – 2011; 9: e81.
  38. Jimenez-Corona M., Cruz-Hervert L., Garcia-Garcia L. et al. Association of diabetes and tuberculosis: impact on treamtent and post-treatmentoutcomes // Thorax. – 2013; 68: 214–20.
  39. Chiang C., Lee J., Yu M. et al. Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death // Int. J. Tuberc. Lung Dis. – 2009; 13: 105–11.
  40. Park S., Shin J., Kim J. et al. The effect of diabetic control status on the clinical features of pulmonary tuberculosis // Eur. J. Clin. Microbiol. Infect Dis. – 2012; 31: 1305–10.
  41. Rekha V., Balasubramanian R., Swaminathan S. et al. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors // Indian J. Med. Res. – 2007; 126: 452–8.
  42. Chernyh N.A. Effektivnost' intensivnoj himioterapii tuberkuleza legkih u bol'nyh saharnym diabetom. Avtoref. dis. … kand. med. nauk. M., 2004; 21 s.
  43. Komissarova O.G. Konjaeva O.O., Berezhnaja O.O. i dr. Effektivnost' lechenija bol'nyh tuberkulezom legkih s mnozhestvennoj i shirokoj lekarstvennoj ustojchivost'ju vozbuditelja v sochetanii s raznymi tipami saharnogo diabeta // Vestnik RGMU. – 2015; 3: 33–7.
  44. Ruslami R., Nijland H., Adhiarta I. et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes // Antimicrob. Agents Chemother. – 2010; 54: 1068–74.
  45. Babalik A., Ulus I., Bakirci N. et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus // Antimicrob. Agents Chemother. – 2013; 57: 5740–2.
  46. Wang C., Yang C., Chen H. et al. Impact of type 2 diabetes on manifestation and treatment outcome of pulmonary tuberculosis // Epidemiol. Infect. – 2009; 137: 203–10.
  47. Oursler K., Moore R., Bishai W. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors // Clin. Infect. Dis. – 2002; 34: 752–9.
  48. Reed G., Choi H., Lee S. et al. Impact of diabetes and smoking on mortality in tuberculosis // PLoS One. – 2013; 8: e58044.
  49. Fielder J., Chaulk C., Dalvi M. et al. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates // Int. J. Tuberc. Lung Dis. – 2002; 6: 1114–7.